Company intelligence / Profile preview

Beijing Zehui Chenxing Biotechnology

Beijing, Beijing Shi, China

Ownership: Private
Development stage: Other

Overview

Beijing Zehui Chenxing Biotechnology is developing stem cell therapies, with its lead product, CAStem Cell, currently in Phase 2 clinical trials for acute graft versus host disease, interstitial lung diseases, ARDS, and meniscus disorders. The company focuses on immune system and respiratory diseases as well as musculoskeletal conditions. Clinical results are not publicly detailed but the programs have advanced to mid-stage clinical development in China.

Therapeutic areas: PulmonologyRheumatologyImmunology
Modalities: Stem cell therapyCell therapy
Industry: Biotech

Drug pipeline

2 assets

CAStem cells

1 more asset in the full pipeline.

Request access →

Partnerships

Institute of Zoology Chinese Academy of Science

Beyond the preview

Go deeper on Beijing Zehui Chenxing Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Zehui Chenxing Biotechnology.

Explore the full profile